Adamis Pharmaceuticals Corp

NASDAQ:ADMP  
0.75
+0.01 (+1.06%)
Products, Regulatory

Adamis Pharma Describes Planned Response to ZIMHI Complete Response Letter

Published: 12/01/2020 14:06 GMT
Adamis Pharmaceuticals Corp (ADMP) - Adamis Pharmaceuticals Describes Planned Response to Zimhi Complete Response Letter.
Adamis Pharmaceuticals Corp - All of Company's Responses to Deficiencies Will Be Submitted Before Year End.
Adamis Pharmaceuticals Corp - If Matter Cannot Be Resolved With FDA Division That Sent Crl, Adamis Intends to Appeal Matter.
Adamis - Intends to Address All Deficiencies Raised in Crl and Request That FDA Approve NDA for Zimhi High Dose Naloxone Injection Product.